Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TNX-1500

Monoclonal antibody · developed by Tonix Pharmaceuticals

Phase 2 Most advanced trial
TNXP Developer
1 Registered trials

What is TNX-1500?

TNX-1500 is an Fc-modified anti-DF154 monoclonal antibody. It is being studied in adult kidney transplant recipients, in a safety study of kidney transplant rejection and immunosuppression.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Therapy area
Immunology
Developer
Tonix Pharmaceuticals, Inc. (TNXP)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07204080 Phase 2 Kidney Transplant Not yet recruiting TNXP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ImmunosuppressionImmunosuppression After Kidney TransplantationKidney TransplantKidney Transplant Failure and Rejection

More from Tonix Pharmaceuticals

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TNXP page.

Follow TNXP, the company behind TNX-1500

See TNXP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TNXP catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.